Eradication of Helicobacter pylori for non-ulcer dyspepsia

Martin, Paul; Soo, Shelly; Deeks, Jonathan J; Delaney, Brendan; Harris, Adam; Innes, Michael; Oakes, Rachel; Wilson, Sue; Roalfe, Andrea; Bennett, Cathy; Forman, David

doi:10.1002/14651858.cd002096

Cited by 205 publications

(140 citation statements)

References 76 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…To date, the correlations of H. pylori infection and the pathogenesis or subgroup of FD are still inconclusive (Mimidis and Tack, 2008). A systematic review demonstrated 10% risk reduction in H. pylori treatment group compared to placebo, and the number needed to treat to improve one case of FD was 14 (Moayyedi et al, 2006). However, a study from the Chinese population showed that odds ratio for improvement in FD after H. pylori eradication was 3.6, imply that the role of H. pylori eradication in FD is better in Asian than Western populations (Jin and Li, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…Seroreactivity to the 89kDa (VacA) and 116kDa (CagA) proteins in H. pylori infected patients is risk indicators for cancer of stomach (Karami et al, 2013;Basiri et al, 2014). H. pylori eradication is not only significantly improve symptoms of FD patients (Moayyedi et al, 2006) but also decreases the gastric cancer incidence in asymptomatic infected Asian persons (Hamajima et al, 2004;Ford et al, 2014). In high prevalence area of gastric cancer, screening and treatment programs for gastric cancer are cost effective (Tsubono et al, 2000;Li et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori Infection Impacts on Functional Dyspepsia in Thailand

Piriyapong

Tangaroonsanti²,

Mahachai³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Helicobacter pylori Infection Impacts on Functional Dyspepsia in Thailand

Piriyapong

Tangaroonsanti²,

Mahachai³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The most recent Cochrane meta-analysis on the subject examined 21 randomized controlled studies on the role of H pylori eradication in the development of dyspeptic symptoms. It was observed a 6% to 14% therapeutic gain, suggesting that eradication of the bacteria may be useful in patients with functional dyspepsia (143) . Among us, Mazzolene et al (134) , in a randomized clinical trial, analyzed 408 patients with functional dyspepsia, with improvement demonstrated in gastrointestinal symptoms (50%) with H pylori eradication in infected patients, compared with the group receiving a proton pump inhibitor in a single daily dose (37%).…”

Section: Statementmentioning

confidence: 97%

“…Cost/benefit analyses of this therapeutic option available today estimate the number needed to treat (NNT) as being between 8 and 14, i.e. 8-14 patients must be treated for a single one to benefit from improved symptoms, particularly epigastric pain (134,143) .…”

Section: Statementmentioning

confidence: 99%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

show abstract

“…Although H. pylori infection induces chronic inflammation and changes mucosal morphology and the function of acid secretion, the effects of H. pylori on gastric motility and sensation remain unclear. However, a systematic review of randomized controlled trials revealed a 10 % relative risk reduction in the H. pylori eradication group compared to the placebo group [28]. Therefore, H. pylori infection is associated with pathogenesis in a subset of functional dyspepsia.…”

Section: H Pylori Infectionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for functional dyspepsia

et al. 2015

View full text Add to dashboard Cite

General interest in functional gastrointestinal disorders is increasing among Japanese doctors as well as patients. This increase can be attributed to a number of factors, including recent increased interest in quality of life and advances in our understanding of the pathophysiology of gastrointestinal disease. Japan recently became the world's first country to list ''functional dyspepsia'' as a disease name for national insurance billing purposes. However, recognition and understanding of functional dyspepsia (FD) remain poor, and no standard treatment strategy has yet been established. Accordingly, the Japanese Society of Gastroenterology (JSGE) developed an evidence-based clinical practice guideline for FD, consisting of five sections: concept, definition, and epidemiology; pathophysiology; diagnosis; treatment; and prognosis and complications. This article summarizes the Japanese guideline, with particular focus on the treatment section. Once a patient is diagnosed with FD, the doctor should carefully explain the pathophysiology and benign nature of this condition, establish a good doctor-patient relationship, and then provide advice for daily living (diet and lifestyle modifications, explanations, and reassurance). The proposed pharmacological treatment is divided into two steps: initial treatment including an acid inhibitory drug (H2RA or PPI) or prokinetics, (strong recommendation); second-line treatment including anxiolytics, antidepressants, and Japanese traditional medicine (weak recommendation). H. pylori eradication, strongly recommended with a high evidence level, is positioned separately from other treatment flows. Conditions that do not respond to these treatment regimens are regarded as refractory FD. Patients will be further examined for other organic disorders or will be referred to specialists using other approaches such as psychosomatic treatment.

show abstract

Eradication of Helicobacter pylori for non-ulcer dyspepsia

Cited by 205 publications

References 76 publications

Helicobacter pylori Infection Impacts on Functional Dyspepsia in Thailand

Helicobacter pylori Infection Impacts on Functional Dyspepsia in Thailand

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Evidence-based clinical practice guidelines for functional dyspepsia

Contact Info

Product

Resources

About